These positive nonclinical data supported initiation of the Phase 1b FALCON trial (NCT07180355), an actively enrolling first-in-human study of SGT-212.
Sunday, November 15, 2026
Nonclinical efficacy and safety evaluation of SGT-212, a novel investigational AAV FXN gene therapy for the treatment of Friedreich’s ataxia
Nonclinical efficacy and safety evaluation of SGT-212, a novel investigational AAV FXN gene therapy for the treatment of Friedreich’s ataxia, Brandon YH Chan, Jun Lee, Jamie Marshall, Matthew Harmelink, Gourav Roy Choudhury, Heather Born, Juliette Hordeaux, James M Wilson, Jessie Hanrahan, Gabriel Brooks, Nicolas Christoforou. Solid Biosciences, Charlestown, USA; University of Pennsylvania, Philadelphia, USA. doi:10.1016/j.nmd.2026.106596
